Literature DB >> 20940402

Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.

Mahendra K Singh1, Eugene Izumchenko, Andres J Klein-Szanto, Brian L Egleston, Marina Wolfson, Erica A Golemis.   

Abstract

Elevated expression of the NEDD9/HEF1/Cas-L scaffolding protein promotes tumor cell invasion and metastasis in multiple cancer cell types. Conversely, generation of mammary tumors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyVT) genetic model is delayed by a Nedd9(-/-) genotype. These activities arise from the role of NEDD9 in assembling complexes and supporting activity of cancer signaling proteins, including FAK, Src, Shc, and AKT, and would support evaluation of NEDD9 expression as an unambiguous biomarker for tumor aggressiveness. However, we here show that despite the initial delay in tumor growth, cells derived from MMTV-PyVT;Nedd9(-/-) tumors are characteristically hyperaggressive versus MMTV-PyVT;Nedd9(+/+) cells in anchorage-independent growth, in growth on three-dimensional matrix produced by tumor-associated fibroblasts, and in formation of tumors after mammary orthotopic reinjection and of lung metastases after tail vein injection. This reversal suggests the specific selection of MMTV-PyVT;Nedd9(-/-) cells for growth in an in vivo microenvironment. Indeed, MMTV-PyVT;Nedd9(-/-) cells have increased cell cycle, centrosomal, and mitotic defects, phenotypes compatible with the increased selection of these cells for aggressive growth. Intriguingly, in spite of their aggressive phenotype, MMTV-PyVT;Nedd9(-/-) cells persistently have low levels of Src activation and are hypersensitive to the Src kinase inhibitor dasatinib. These studies identify NEDD9 as a complex modulator of different aspects of mammary tumor growth. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940402      PMCID: PMC2970659          DOI: 10.1158/0008-5472.CAN-10-0353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics.

Authors:  G M O'Neill; E A Golemis
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells.

Authors:  Toru Hirota; Naoko Kunitoku; Takashi Sasayama; Tomotoshi Marumoto; Dongwei Zhang; Masayuki Nitta; Katsuyoshi Hatakeyama; Hideyuki Saya
Journal:  Cell       Date:  2003-09-05       Impact factor: 41.582

3.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.

Authors:  Richard Bayliss; Teresa Sardon; Isabelle Vernos; Elena Conti
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

4.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

5.  LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.

Authors:  Yoon-La Choi; Melanie Bocanegra; Mi Jeong Kwon; Young Kee Shin; Seok Jin Nam; Jung-Hyun Yang; Jessica Kao; Andrew K Godwin; Jonathan R Pollack
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

6.  Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway.

Authors:  G A van Seventer; H J Salmen; S F Law; G M O'Neill; M M Mullen; A M Franz; S B Kanner; E A Golemis; J M van Seventer
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

7.  A novel ability of Smad3 to regulate proteasomal degradation of a Cas family member HEF1.

Authors:  X Liu; A E Elia; S F Law; E A Golemis; J Farley; T Wang
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

Review 8.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

9.  Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity.

Authors:  L-C Bui; C Tomkiewicz; A Chevallier; S Pierre; A-S Bats; S Mota; J Raingeaud; J Pierre; M Diry; C Transy; M Garlatti; R Barouki; X Coumoul
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

10.  Dissection of HEF1-dependent functions in motility and transcriptional regulation.

Authors:  Sarah J Fashena; Margret B Einarson; Geraldine M O'Neill; Christos Patriotis; Erica A Golemis
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

View more
  22 in total

Review 1.  Aurora kinases in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Barbara Burtness; Igor Astsaturov; Erica A Golemis
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

2.  Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1-Dependent Trafficking of Integrins.

Authors:  Polina Y Kozyulina; Yuriy V Loskutov; Varvara K Kozyreva; Anuradha Rajulapati; Ryan J Ice; Brandon C Jones; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2014-10-15       Impact factor: 5.852

3.  Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer.

Authors:  Emil Štajduhar; Mirela Sedić; Tanja Leniček; Petra Radulović; Aleksandar Kerenji; Božo Krušlin; Krešimir Pavelić; Sandra Kraljević Pavelić
Journal:  Tumour Biol       Date:  2014-03-28

4.  Overexpression of Nedd9 is a prognostic marker of human gastric cancer.

Authors:  Qi Zhang; Huiju Wang; Yingyu Ma; Jun Zhang; Xujun He; Jie Ma; Zhong-Sheng Zhao
Journal:  Med Oncol       Date:  2014-06-07       Impact factor: 3.064

Review 5.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  Nedd9 restrains renal cystogenesis in Pkd1-/- mice.

Authors:  Anna S Nikonova; Olga V Plotnikova; Victoria Serzhanova; Andrey Efimov; Igor Bogush; Kathy Q Cai; Harvey H Hensley; Brian L Egleston; Andres Klein-Szanto; Tamina Seeger-Nukpezah; Erica A Golemis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

7.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

Review 8.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

Review 9.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

10.  A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Authors:  J L Little; V Serzhanova; E Izumchenko; B L Egleston; E Parise; A J Klein-Szanto; G Loudon; M Shubina; S Seo; M Kurokawa; M F Ochs; E A Golemis
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.